ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer

被引：0
|
作者：
Hanker, Ariella B.
Estrada, Monica Valeria
Zhao, Junfei
Cheng, Feixiong
Moore, Preston D.
Tyson, Darren
Sanchez, Violeta
Rexer, Brent N.
Sanders, Melinda
Zhao, Zhongming
Stricker, Thomas P.
Arteaga, Carlos L.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-302
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
302
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Role of EGFR, HER2 and PIK3CA alterations in male breast cancer
    Rizzolo, P.
    Silvestri, V.
    Falchetti, M.
    Zanna, I.
    Palli, D.
    Ottini, L.
    EJC SUPPLEMENTS, 2010, 8 (05): : 24 - 24
  • [42] Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
    She, Qing-Bai
    Chandarlapaty, Sarat
    Ye, Qing
    Lobo, Jose
    Haskell, Kathleen M.
    Leander, Karen R.
    DeFeo-Jones, Deborah
    Huber, Hans E.
    Rosen, Neal
    PLOS ONE, 2008, 3 (08):
  • [43] MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers
    Hoe, Nicholas
    Mateling, Michael
    Ma, Yating
    Jin, Kelly
    Zhou, JinYao
    Kirkland, Richard
    Kuy, Crystal
    Liu, Xinjun
    Kim, Phillip
    Singh, Sharat
    CANCER RESEARCH, 2013, 73 (08)
  • [44] Upregulation of HER3 (ErbB3) levels and function counteracts the antitumor effect of HER2 and PI3K inhibitors
    Garrett, Joan
    Rinehart, Cammie
    Chakrabarty, Anindita
    Dave, Bhuvanesh
    Pao, William
    Manning, Charles
    Chang, Jenny
    Arteagal, Carlos
    CANCER RESEARCH, 2011, 71
  • [45] PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
    Chung, Wei-Pang
    Huang, Wei-Lun
    Lee, Chun-Hui
    Hsu, Hui-Ping
    Huang, Wan-Ling
    Liu, You-Yu
    Su, Wu-Chou
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (07): : 3067 - +
  • [46] Dual inhibition of the PI3K-mTOR signaling in combination with HER2 inhibitor is necessary for maximal antitumor activity in HER2+breast cancer cells
    De, Pradip
    Sun, Yuliang
    Carlson, Jennifer
    Friedman, Lori
    Dey, Nandini
    Leyland-Jones, Brian
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [47] Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
    Garrett, Joan T.
    Sutton, Cammie R.
    Kurupi, Richard
    Bialucha, Carl Uli
    Ettenberg, Seth A.
    Collins, Scott D.
    Sheng, Qing
    Wallweber, Jerry
    DeFazio-Eli, Lisa
    Arteaga, Carlos L.
    CANCER RESEARCH, 2013, 73 (19) : 6013 - 6023
  • [48] PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
    Serra, V.
    Scaltriti, M.
    Prudkin, L.
    Eichhorn, P. J. A.
    Ibrahim, Y. H.
    Chandarlapaty, S.
    Markman, B.
    Rodriguez, O.
    Guzman, M.
    Rodriguez, S.
    Gili, M.
    Russillo, M.
    Parra, J. L.
    Singh, S.
    Arribas, J.
    Rosen, N.
    Baselga, J.
    ONCOGENE, 2011, 30 (22) : 2547 - 2557
  • [49] PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
    V Serra
    M Scaltriti
    L Prudkin
    P J A Eichhorn
    Y H Ibrahim
    S Chandarlapaty
    B Markman
    O Rodriguez
    M Guzman
    S Rodriguez
    M Gili
    M Russillo
    J L Parra
    S Singh
    J Arribas
    N Rosen
    J Baselga
    Oncogene, 2011, 30 : 2547 - 2557
  • [50] Trefoil Factor 3 (TFF3) is HER2-regulated and substitutes for HER2 signalling in acquired trastuzumab resistance in HER2+/ER+ breast cancer
    Chong, Q. Y.
    Pandey, V. K.
    Banerjee, A.
    Chen, Y. J.
    You, M. L.
    Lobie, P. E.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S131 - S131
12345